TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (Pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma
TuHURA Biosciences, formed by CohBar and Morphogenesis, a UF startup, has announced the initiation of its Phase 3 accelerated approval trial of IFx-2.0, TuHURA's lead innate immune agonist, in patients with advanced or metastatic Merkel cell carcinoma (MCC).
Positive Results in Cancer Vaccine Trial for Merkel Cell Carcinoma and Cutaneous Squamous Cell Carcinoma
Morphogenesis, Inc., a biotechnology company focused on developing cancer vaccines, in partnership with CohBar, believes they have met their milestone with IFx-HU2.0, a cancer vaccine studied in advanced Merkel cell carcinoma and squamous cell carcinoma.
CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy
CohBar, Inc. and Morphogenesis, Inc., a privately-held Phase 2/3 clinical-stage biotechnology company developing novel personalized cancer vaccines and tumor microenvironment modulators to overcome resistance to current immunotherapies, have entered into a definitive agreement for an all-stock transaction forming a company combining expertise and resources to advance a late-stage oncology pipeline.
Tampa’s Morphogenesis Wants To Cure Cancer With an Affordable Shot
A group of scientists in Tampa is working to make treating cancer as easy as getting a shot. While most of today's cancer treatments tend to be toxic and expensive, UF startup and UF Innovate | Sid Martin Biotech alum Morphogenesis, Inc., a clinical-stage biotechnology company, is working to develop immunotherapies that are safe and affordable.
Morphogenesis Awarded SBIR Funding for Cervical Cancer Therapy
UF startup and UF Innovate | Sid Martin Biotech alum Morphogenesis, Inc., a clinical-stage biotechnology company, has obtained funding to develop a new therapeutic drug to treat cervical cancer.
Morphogenesis’ Skin Cancer Vaccine Gets FDA ‘Fast Track’
Tampa company Morphogenesis, a UF startup, has received a “fast track” designation for its skin cancer vaccination from the United States Food and Drug Administration.
Tampa Company Developing Cancer Vaccines Could Receive Grant To Research Cervical Cancer Vaccine
UF startup and UF Innovate | Sid Martin Biotech alum Morphogenesis, Inc., a Tampa-based company that has been researching and developing a vaccine for certain types of skin cancers, could be soon receiving a grant to begin research on a cervical cancer treatment for underprivileged women.
Skin Cancer Vaccine Developed by Tampa Company Enters Phase 1 of Clinical Trial
UF startup and UF Innovate | Sid Martin Biotech alum Morphogenesis, Inc. completed its first-in-human phase one trial in cutaneous melanoma at Moffitt Cancer Center within the past year and has now moved into studying patients in earlier stages of skin cancers.
When Entrepreneurship Meets Healthcare: Lessons in Playing the Long Game
One medtech immunotherapy company called Morphogenesis in Tampa, Florida, a UF startup and UF Innovate | Sid Martin Biotech alum, is currently working on one of the highest-stakes medical issues of all: treating cancer.
Pets, Perseverance, and Manufacturing Facility Bring Biotech Success
Patricia Lawman, co-founder and CEO of the biotech firm Morphogenesis, a UF startup and UF Innovate | Sid Martin Biotech graduate company, has always been amazed at how our bodies can defeat illnesses and usually do it better than drugs.
